Encompass Health 10-Q: Q3 Revenue Up 8.9% to $1.61B, Bad-Debt Reserves Rise on Billing Disruption
EHC sits 47% above its 52-week low of $92.77.
Summary
Encompass Health's Q3 10-Q confirms $1.61B revenue (+8.9%) and $1.50 diluted EPS, but flags bad-debt reserves rising to 2.7% of revenue after a billing system disruption and a big expansion of Medicare claim review starting January 2027.
Key Events · Earnings and Guidance · EHC
-
Q3 Revenue Grows 8.9% to $1.61B
Net operating revenues were $1,609.5 million versus $1,477.5 million a year earlier, with diluted EPS of $1.50 ($1.51 from continuing operations) and Adjusted EBITDA of $346.6 million versus $300.1 million.
-
Bad-Debt Reserves Jump on Billing Disruption
Revenue reserves related to bad debt rose to 2.7% of net operating revenues from 1.9%, which the company attributes to a billing and collecting disruption following a system conversion in the second quarter of 2026.
-
Medicare Claim Review Expansion From 2027
CMS expanded the Review Choice Demonstration to all IRFs billing a certain MAC effective January 1, 2027, covering 108 of the company's hospitals, or roughly 63% of its IRF Medicare claims.
-
$1.0B Buyback Authorization, $955M Left
The board reset the repurchase authorization to $1.0 billion on July 23, 2026; about $955 million remained as of September 30, 2026, after 1.9 million shares repurchased for $203.7 million in the first nine months.
Analysis · EHC · Industrial Applications And Services
The headline numbers were already out on October 28, but the full 10-Q carries the detail that matters: revenue reserves tied to bad debt jumped to 2.7% of net operating revenues from 1.9% after a billing and collection disruption following a second-quarter system conversion, which is a real cash-collection risk rather than an accounting quirk. Against that, Adjusted EBITDA rose to $346.6 million from $300.1 million and the company still has roughly $955 million left on a $1.0 billion buyback authorization, so capital returns remain intact. The other item to price in is regulatory: CMS expanded the Review Choice Demonstration to all IRFs billing a certain MAC effective January 1, 2027, putting 108 of the company's hospitals — about 63% of its IRF Medicare claims — under 100% claim review, which raises denial and appeal exposure.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EHC was trading at $136.40 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $92.77 to $139.12. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.